Fingolimod Bluefish
Sphingosine-1-phosphate (S1P) receptor modulator for relapsing-remitting multiple sclerosis
Fingolimod Bluefish is a disease-modifying therapy used to treat relapsing-remitting multiple sclerosis (RRMS). It works by trapping certain white blood cells (lymphocytes) in lymph nodes, preventing them from attacking the protective myelin sheath around nerve fibers in the brain and spinal cord. This comprehensive guide covers dosage, side effects, drug interactions, first-dose monitoring requirements, and important safety information based on current EMA and FDA guidelines.
Quick Facts
Key Takeaways
- Fingolimod Bluefish is an oral once-daily capsule that significantly reduces relapse rates in relapsing-remitting multiple sclerosis (RRMS)
- First-dose monitoring for at least 6 hours is mandatory due to potential cardiac effects including bradycardia and atrioventricular block
- Regular blood tests, eye examinations, and liver function monitoring are required throughout treatment
- Contraindicated in pregnancy — effective contraception must be used during treatment and for 2 months after stopping
- Live vaccines must be avoided during treatment; vaccination status should be checked before starting fingolimod
What Is Fingolimod Bluefish and What Is It Used For?
Fingolimod Bluefish belongs to a class of medications known as sphingosine-1-phosphate (S1P) receptor modulators. It is a generic version of the original fingolimod product and contains the same active substance at the same strength (0.5 mg hard capsules). The medication is approved by the European Medicines Agency (EMA) and is prescribed for the treatment of highly active relapsing-remitting multiple sclerosis in adults, as well as in children and adolescents aged 10 years and older.
Multiple sclerosis (MS) is a chronic autoimmune disease in which the immune system mistakenly attacks the protective myelin sheath surrounding nerve fibers in the brain and spinal cord. This leads to inflammation, demyelination, and progressive neurological damage. In relapsing-remitting MS, the most common form, patients experience episodes of new or worsening neurological symptoms (relapses) followed by periods of partial or complete recovery (remissions).
Fingolimod works through a unique mechanism of action. After oral ingestion, it is phosphorylated in the body to its active form, fingolimod-phosphate. This active metabolite binds to sphingosine-1-phosphate receptors on the surface of lymphocytes (a type of white blood cell). By binding to these receptors, fingolimod prevents lymphocytes from leaving lymph nodes, effectively sequestering them and reducing the number of circulating lymphocytes that could cross the blood-brain barrier and attack myelin.
The clinical efficacy of fingolimod was established in several landmark clinical trials. The FREEDOMS trial (FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis) demonstrated that fingolimod 0.5 mg reduced the annualized relapse rate by 54% compared to placebo over 24 months. The TRANSFORMS trial showed a 52% reduction in relapse rate compared to intramuscular interferon beta-1a. These trials also showed benefits in reducing MRI lesion activity and slowing brain volume loss.
Indications
Fingolimod Bluefish is indicated as a single disease-modifying therapy in highly active relapsing-remitting multiple sclerosis for the following patient groups:
- Adults with high disease activity despite a full and adequate course of treatment with at least one disease-modifying therapy, or with rapidly evolving severe RRMS defined by 2 or more disabling relapses in one year and evidence of disease activity on MRI
- Children and adolescents aged 10 years and older with highly active disease despite adequate treatment with at least one disease-modifying therapy
What Should You Know Before Taking Fingolimod Bluefish?
Fingolimod is a potent immunomodulatory medication that requires thorough medical evaluation before treatment can begin. Your prescribing neurologist will conduct a comprehensive assessment to ensure that fingolimod is safe and appropriate for you. Understanding the contraindications, warnings, and precautions is essential for safe treatment.
Contraindications
You must not take Fingolimod Bluefish if any of the following apply to you:
- Known hypersensitivity to fingolimod or any excipient in the formulation
- Known immunodeficiency syndrome
- Patients with increased risk of opportunistic infections, including those who are immunocompromised (including those currently receiving immunosuppressive therapies or those immunocompromised by prior therapies)
- Severe active infections or active chronic infections (hepatitis, tuberculosis)
- Known active malignancies, except basal cell carcinoma of the skin
- Severe liver impairment (Child-Pugh class C)
- Myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure, or New York Heart Association (NYHA) Class III/IV heart failure within the preceding 6 months
- History of second-degree Mobitz type II or higher atrioventricular (AV) block, sick sinus syndrome, or sino-atrial heart block, unless the patient has a functioning pacemaker
- Significant QT prolongation (QTc > 500 ms)
- Treatment with Class Ia or Class III antiarrhythmic drugs
- Pregnancy or women of childbearing potential not using effective contraception
Warnings and Precautions
Fingolimod causes a transient decrease in heart rate and may cause atrioventricular conduction delays when treatment is initiated. All patients must undergo first-dose monitoring with continuous ECG for at least 6 hours after the initial dose. If treatment is interrupted for more than 14 days, first-dose monitoring must be repeated.
The following conditions require special caution and close monitoring:
- Cardiac effects: Fingolimod causes a dose-dependent reduction in heart rate, with the maximum effect typically occurring within 6 hours of the first dose. Heart rate usually begins to increase after day 1 and normalizes within one month. AV conduction delays (first-degree and, less commonly, second-degree AV block) may also occur.
- Infections: Fingolimod reduces the peripheral lymphocyte count to approximately 20-30% of baseline values, increasing susceptibility to infections. Cases of progressive multifocal leukoencephalopathy (PML), cryptococcal infections, and herpes viral infections have been reported. A complete blood count should be obtained before starting treatment.
- Macular edema: Fingolimod increases the risk of macular edema. An ophthalmological evaluation is required 3-4 months after starting treatment and whenever visual symptoms occur. Patients with diabetes mellitus or a history of uveitis are at increased risk.
- Liver effects: Fingolimod may cause elevated liver transaminases. Liver function tests should be performed before starting treatment, then at months 1, 3, 6, 9, and 12, and periodically thereafter.
- Blood pressure effects: Fingolimod may cause a modest increase in blood pressure. Blood pressure should be monitored regularly during treatment.
- Posterior reversible encephalopathy syndrome (PRES): Rare cases have been reported. If PRES is suspected, fingolimod should be discontinued immediately.
- Skin cancer: Cases of basal cell carcinoma and, rarely, melanoma have been reported. Skin examination is recommended at treatment initiation and at least annually thereafter.
Pregnancy and Breastfeeding
Fingolimod is contraindicated during pregnancy. Animal studies have shown reproductive toxicity including fetal malformations. Fingolimod must be stopped at least 2 months before a planned pregnancy.
Women of childbearing potential must be informed of the serious risk to the fetus, the need for effective contraception during treatment and for 2 months after discontinuation, and the requirement for a negative pregnancy test before starting treatment. If a woman becomes pregnant while taking fingolimod, the medication should be discontinued immediately, and the patient should be referred for specialist monitoring.
Fingolimod is excreted in breast milk in animal studies. Due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment with fingolimod or for 2 months after the last dose.
For men, fingolimod has no known effects on male fertility based on available preclinical data. However, patients should discuss family planning with their healthcare provider before starting treatment.
How Does Fingolimod Bluefish Interact with Other Drugs?
Drug interactions are a critical consideration when prescribing fingolimod. Because fingolimod affects heart rate, immune function, and is metabolized by the cytochrome P450 enzyme system (primarily CYP4F2, with some involvement of CYP2D6, CYP2E1, CYP3A4, and CYP4F12), numerous potential interactions exist. Your healthcare provider must review all current medications, including prescription drugs, over-the-counter medicines, and herbal supplements, before starting treatment.
Major Interactions
The following drug combinations are considered clinically significant and may require dose adjustments, enhanced monitoring, or avoidance of co-administration:
| Interacting Drug / Class | Effect | Recommendation |
|---|---|---|
| Beta-blockers (atenolol, metoprolol, propranolol) | Additive heart rate reduction; risk of severe bradycardia | Avoid if possible; if co-administration is necessary, cardiology consultation and extended first-dose monitoring recommended |
| Heart rate-lowering calcium channel blockers (diltiazem, verapamil) | Additive bradycardia and AV conduction delays | Avoid concomitant use; extended cardiac monitoring if unavoidable |
| Class Ia antiarrhythmics (quinidine, procainamide, disopyramide) | Risk of torsades de pointes in patients with bradycardia | Contraindicated — do not co-administer |
| Class III antiarrhythmics (amiodarone, sotalol, dofetilide) | Risk of torsades de pointes in patients with bradycardia | Contraindicated — do not co-administer |
| QT-prolonging medications (certain antipsychotics, antibiotics, antidepressants) | Additive QT prolongation risk in the setting of fingolimod-induced bradycardia | Specialist cardiology review before initiating; ECG monitoring |
| Immunosuppressants (azathioprine, cyclosporine, methotrexate) | Additive immunosuppression; significantly increased infection risk | Avoid concomitant use; adequate washout period required when switching |
| Live attenuated vaccines (MMR, varicella, yellow fever, live influenza) | Risk of infection from live vaccine; reduced vaccine efficacy | Contraindicated during treatment and for 2 months after stopping; complete all vaccinations at least 1 month before starting fingolimod |
Minor Interactions
The following interactions are generally manageable but should be documented and monitored:
| Interacting Drug / Class | Effect | Recommendation |
|---|---|---|
| Ketoconazole (CYP3A4/CYP4F2 inhibitor) | Increases fingolimod exposure by approximately 1.7-fold | Use with caution; monitor for enhanced effects |
| Carbamazepine (CYP3A4 inducer) | May reduce fingolimod exposure by approximately 40% | Monitor clinical response; consider alternative anticonvulsant |
| Inactivated vaccines (influenza, COVID-19 mRNA) | Reduced immune response; vaccines may be less effective | Can be administered but efficacy may be diminished; consider antibody titer testing post-vaccination |
| Corticosteroids (short-course) | Additive immune suppression; generally well-tolerated for relapse treatment | Short courses (e.g., methylprednisolone for relapses) are acceptable; avoid prolonged concomitant use |
When switching from other disease-modifying therapies to fingolimod, adequate washout periods must be observed to avoid overlapping immunosuppression. For natalizumab, a washout of at least 2-3 months is typically recommended. For teriflunomide, an accelerated elimination procedure may be required. Your neurologist will determine the appropriate timing based on your specific treatment history and disease activity.
What Is the Correct Dosage of Fingolimod Bluefish?
Fingolimod Bluefish should only be prescribed by physicians experienced in the management of multiple sclerosis. The dosing regimen is straightforward, but initiation requires careful medical supervision due to the first-dose cardiac effects. It is essential to follow your prescribing physician's instructions exactly and not to modify the dose without medical guidance.
Adults
Standard Adult Dose
One 0.5 mg hard capsule taken orally, once daily, with or without food. The capsule should be swallowed whole with water and should not be opened, crushed, or chewed. Treatment should be taken at approximately the same time each day to maintain consistent blood levels.
No dose adjustment is required based on sex, ethnicity, or body weight in adult patients. Fingolimod can be taken with or without food, as food does not significantly affect its absorption or bioavailability. The steady-state blood concentration is reached within 1-2 months of daily dosing.
Children and Adolescents (aged 10 years and older)
Pediatric Dosing
Body weight ≤ 40 kg: 0.25 mg once daily (a 0.25 mg capsule formulation may be required; consult your pharmacist or physician).
Body weight > 40 kg: 0.5 mg once daily (same as adult dose).
Children who start on the 0.25 mg dose and subsequently reach a stable body weight above 40 kg may be switched to the 0.5 mg dose at the discretion of their treating neurologist. Re-initiation of first-dose monitoring is required when switching doses. Fingolimod is not approved for use in children under 10 years of age due to insufficient safety and efficacy data.
Elderly Patients (aged 65 years and older)
Elderly Dosing
Clinical experience in patients over 65 years of age is limited. Fingolimod should be used with caution in this population. The same 0.5 mg daily dose applies, but closer monitoring is recommended given the higher likelihood of hepatic, renal, or cardiac comorbidities.
Renal and Hepatic Impairment
No dose adjustment is needed for patients with mild to moderate renal impairment. For patients with severe renal impairment, use with caution as fingolimod-phosphate blood levels may be increased by approximately 14%. In patients with mild to moderate hepatic impairment (Child-Pugh A or B), no dose adjustment is required, but caution is advised. Fingolimod is contraindicated in patients with severe hepatic impairment (Child-Pugh C).
Missed Dose
If a dose is missed, the missed dose should be skipped and the next dose should be taken at the regular scheduled time. Do not take a double dose to make up for a missed dose. However, specific rules apply depending on the duration of treatment interruption:
- Within the first 2 weeks of treatment: If even a single dose is missed, contact your physician immediately. Re-initiation of first-dose monitoring may be necessary.
- After 2 weeks of continuous treatment: If 1 day is missed, resume the normal dosing schedule the next day.
- Treatment interruption of more than 14 consecutive days: First-dose monitoring must be repeated when restarting treatment, as the effects on heart rate and AV conduction may recur.
Overdose
In case of overdose, the most important clinical effect to be anticipated is bradycardia. In healthy volunteers given a single dose of 5 mg (10 times the recommended dose), a mild decrease in heart rate was observed. In the post-marketing setting, cases of overdose up to 20-fold have been reported. These patients were generally asymptomatic or experienced mild symptoms such as chest tightness.
If overdose occurs, contact your physician or poison control center immediately. Treatment is supportive. Fingolimod cannot be removed by dialysis or plasma exchange. The patient should be monitored overnight with continuous ECG monitoring. Atropine or isoprenaline may be administered for symptomatic bradycardia.
What Are the Side Effects of Fingolimod Bluefish?
Like all medicines, Fingolimod Bluefish can cause side effects, although not everybody gets them. Most side effects are mild to moderate in severity and tend to decrease or resolve with continued treatment. However, some side effects can be serious and require immediate medical attention. Understanding the frequency and nature of potential side effects helps patients and their caregivers recognize problems early and seek appropriate care.
Side effects are classified according to the following frequency convention used by the European Medicines Agency (EMA):
Very Common (affects more than 1 in 10 people)
Frequency: > 10%
- Influenza viral infections
- Headache
- Cough
- Diarrhea
- Elevated liver transaminases (ALT/AST)
- Back pain
- Lymphopenia (reduced lymphocyte count — expected pharmacological effect)
Common (affects 1 to 10 in 100 people)
Frequency: 1% – 10%
- Herpes viral infections (oral herpes, herpes zoster)
- Bronchitis, sinusitis
- Gastroenteritis
- Tinea infections (fungal skin infections)
- Depression, anxiety
- Dizziness, paresthesia (tingling/numbness)
- Migraine
- Blurred vision, eye pain
- Bradycardia (slow heart rate, especially at first dose)
- Atrioventricular block (first-degree or second-degree)
- Hypertension (high blood pressure)
- Dyspnea (shortness of breath)
- Eczema, alopecia (hair loss), pruritus (itching)
- Asthenia (weakness/fatigue)
- Elevated blood triglycerides
- Leukopenia (reduced white blood cell count)
- Macular edema
Uncommon (affects 1 to 10 in 1,000 people)
Frequency: 0.1% – 1%
- Pneumonia
- Nausea
- Lymphoma
- Squamous cell carcinoma of the skin
- Thrombocytopenia (low platelet count)
- Peripheral edema
- Depressed mood
Rare (affects less than 1 in 1,000 people)
Frequency: < 0.1%
- Progressive multifocal leukoencephalopathy (PML)
- Cryptococcal infections (meningitis)
- Posterior reversible encephalopathy syndrome (PRES)
- Basal cell carcinoma
- Melanoma
- Kaposi sarcoma
- Hemophagocytic syndrome
- Peripheral neuropathy
- Immune reconstitution inflammatory syndrome (after discontinuation)
Contact your doctor or seek emergency care immediately if you experience: signs of serious infection (high fever, severe headache, stiff neck, confusion, visual disturbances); chest pain or irregular heartbeat; sudden vision changes or eye pain; severe abdominal pain or yellowing of the skin/eyes; persistent unexplained skin changes; or signs of severe allergic reaction (swelling, difficulty breathing).
It is important to note that lymphocyte count reduction is an expected and desired pharmacological effect of fingolimod. Peripheral blood lymphocyte counts typically decrease to approximately 20-30% of the baseline value within 4-6 hours of the first dose. This low lymphocyte count is maintained with continuous daily dosing and is the mechanism by which fingolimod exerts its therapeutic effect in multiple sclerosis. After stopping fingolimod, lymphocyte counts generally return to the normal range within 1-2 months.
Long-term safety data from clinical trials and post-marketing surveillance spanning more than 15 years of real-world use support a generally favorable benefit-risk profile for fingolimod. However, vigilance for rare serious events, particularly PML and serious infections, remains important throughout the duration of treatment.
How Should You Store Fingolimod Bluefish?
Proper storage of medications is essential to maintain their efficacy and safety. Fingolimod Bluefish hard capsules should be stored under specific conditions to ensure the medication remains stable and effective throughout its shelf life.
- Temperature: Store below 25°C (77°F). Do not freeze. Avoid exposure to excessive heat or direct sunlight.
- Moisture protection: Store in the original blister packaging to protect from moisture. Do not remove capsules from the blister until ready to take them.
- Child safety: Keep out of the sight and reach of children.
- Expiry date: Do not use this medicine after the expiry date stated on the carton and blister after "EXP." The expiry date refers to the last day of that month.
- Disposal: Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
If capsules have been stored at a temperature above 25°C for a prolonged period or have been exposed to moisture, consult your pharmacist before use. Damaged or discolored capsules should not be taken. If your medication appears different from usual (change in color, texture, or smell), contact your pharmacist for advice before continuing treatment.
What Does Fingolimod Bluefish Contain?
Understanding the complete composition of your medication is important, especially if you have known allergies or intolerances to specific pharmaceutical ingredients. Each Fingolimod Bluefish 0.5 mg hard capsule contains the following:
Active Substance
Each capsule contains 0.5 mg fingolimod (as fingolimod hydrochloride). The hydrochloride salt form enhances the stability and absorption of the active substance. The equivalent amount of fingolimod hydrochloride per capsule is 0.56 mg.
Excipients (Inactive Ingredients)
The inactive ingredients serve various pharmaceutical purposes such as ensuring uniform distribution of the active substance, aiding in capsule filling, and maintaining stability:
- Mannitol: A sugar alcohol used as a filler and bulking agent
- Hydroxypropyl cellulose: A binder that helps the capsule contents hold together
- Hydroxypropyl betadex: A cyclodextrin derivative that improves drug solubility and stability
- Magnesium stearate: A lubricant that prevents the powder from sticking to manufacturing equipment
Capsule Shell
The hard capsule shell is composed of gelatin and may contain colorants such as titanium dioxide (E171) and iron oxide yellow (E172). Patients with known gelatin sensitivity should inform their healthcare provider before starting treatment.
Fingolimod Bluefish does not contain lactose, gluten, or sucrose. It is suitable for patients with lactose intolerance, celiac disease, or hereditary fructose intolerance. If you have any concerns about specific ingredients, consult your pharmacist or prescribing physician.
Frequently Asked Questions About Fingolimod Bluefish
References
This article is based on the following peer-reviewed sources and regulatory documents:
- European Medicines Agency (EMA). Fingolimod — Summary of Product Characteristics (SmPC). Updated 2024. Available at: www.ema.europa.eu
- Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis (FREEDOMS study). N Engl J Med. 2010;362(5):387-401. doi:10.1056/NEJMoa0909494
- Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis (TRANSFORMS study). N Engl J Med. 2010;362(5):402-415. doi:10.1056/NEJMoa0907839
- Chitnis T, Arnold DL, Banwell B, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis (PARADIGMS study). N Engl J Med. 2018;379(11):1017-1027. doi:10.1056/NEJMoa1800149
- U.S. Food and Drug Administration (FDA). Fingolimod prescribing information. Updated 2024. Available at: www.accessdata.fda.gov
- National Institute for Health and Care Excellence (NICE). Technology appraisal guidance: Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis. TA254. 2012.
- Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018;90(17):777-788. doi:10.1212/WNL.0000000000005347
- World Health Organization (WHO). Model List of Essential Medicines. 23rd list, 2023. Available at: www.who.int
- British National Formulary (BNF). Fingolimod monograph. Available at: bnf.nice.org.uk
Editorial Team
This article was written and reviewed by iMedic's medical editorial team, which includes board-certified neurologists and clinical pharmacologists with expertise in multiple sclerosis and immunomodulatory therapies.
iMedic Medical Editorial Team — Specialists in Neurology and Clinical Pharmacology
iMedic Medical Review Board — Independent panel following EMA, FDA, and NICE guidelines
Level 1A: Based on systematic reviews and meta-analyses of randomized controlled trials (GRADE framework)
No commercial funding. No pharmaceutical sponsorship. Independent medical information.